1.辽宁中医药大学附属医院,辽宁省沈阳市皇姑区北陵大街33号,110032
2.辽宁中医药大学附属第四医院
3.辽宁中医药大学
4.辽宁中医药大学附属第二医院
yanzhang1016@126.com
收稿:2023-09-30,
修回:2023-11-26,
纸质出版:2024-02-17
移动端阅览
张艳,何佳,张伟等.补肾活血方联合常规西药治疗射血分数中间值心衰气虚血瘀证患者129例随机对照临床观察[J].中医杂志,2024,65(04):376-381.
ZHANG Yan,HE Jia,ZHANG Wei,et al.Bushen Huoxue Formula (补肾活血方) Combined with Conventional Western Medicine for 129 Patients of Heart Failure with Mid-range Ejection Fraction with Syndrome of Qi Deficiency and Blood Stasis:A Randomized Controlled Trial[J].Journal of Traditional Chinese Medicine,2024,65(04):376-381.
张艳,何佳,张伟等.补肾活血方联合常规西药治疗射血分数中间值心衰气虚血瘀证患者129例随机对照临床观察[J].中医杂志,2024,65(04):376-381. DOI: 10.13288/j.11-2166/r.2024.04.008.
ZHANG Yan,HE Jia,ZHANG Wei,et al.Bushen Huoxue Formula (补肾活血方) Combined with Conventional Western Medicine for 129 Patients of Heart Failure with Mid-range Ejection Fraction with Syndrome of Qi Deficiency and Blood Stasis:A Randomized Controlled Trial[J].Journal of Traditional Chinese Medicine,2024,65(04):376-381. DOI: 10.13288/j.11-2166/r.2024.04.008.
目的
2
评价补肾活血方治疗射血分数中间值心衰(HFmrEF)气虚血瘀证的临床疗效。
方法
2
将HFmrEF气虚血瘀证患者277例随机分为治疗组139例、对照组138例,对照组给予常规西药治疗,治疗组在对照组基础上加用补肾活血方,两组均治疗8周。比较治疗前后两组患者左心室射血分数(LVEF)、N末端B型利钠肽原(NT-pro BNP)水平、心功能分级、明尼苏达心力衰竭生活质量评分、焦虑评分、抑郁评分,以及治疗后6个月主要不良心血管事件发生率、再住院率情况。
结果
2
治疗组脱落10例、对照组脱落6例,实际完成治疗组129例、对照组132例。与本组治疗前比较,两组患者治疗后LVEF升高、NT-pro BNP水平降低(
P
<0.05);治疗后治疗组与对照组比较,LVEF升高、NT-pro BNP水平降低(
P
<0.05)。治疗组心功能分级改善总有效率(97.67%,126例/129例)高于对照组(84.09%,111例/132例)(
P
<0.05)。治疗后两组患者明尼苏达心力衰竭生活质量评分、焦虑评分、抑郁评分均较治疗前降低(
P
<0.05),且治疗组上述评分均低于对照组(
P
<0.05)。治疗后6个月两组患者均无死亡事件发生,治疗组主要不良心血管事件发生率(25.58%,33例/129例)与对照组(33.33%,44例/132例)比较差异无统计学意义(
P
>0.05);治疗组再住院率(14.73%,19例/129例)低于对照组(30.30%,40例/132例)(
P
<0.05)。
结论
2
补肾活血方可增加HFmrEF气虚血瘀证患者的LVEF,降低NT-pro BNP,提高生活质量,改善患者焦虑抑郁状态,降低再住院率。
Objective
2
To evaluate the clinical effectiveness of
Bushen Huoxue Formula
(补肾活血方) in the treatment of heart failure with mid-range ejection fraction.
Methods
2
A total of 277 patients of heart failure with mid-range ejection fraction with syndrome of
qi
deficiency and blood stasis were randomly divided into the treatment group (139 cases) and the control group (138 cases). The control group was given conventional western medicine, and the treatment group was given
Bushen Huoxue Formula
on the basis of the control group. Both groups were treated for 8 weeks. Left ventricular ejection fraction (LVEF), N-terminal B-type natriuretic peptide (NT-pro BNP) level, cardiac function grade, Minnesota heart failure quality of life score, anxiety score, depression score, and the major incidence of cardiovascular adverse events and re-hospitalization rate after 6-month treatment were compared between the two groups before and after treatment.
Results
2
There were 10 withdrawals in the treatment group and 6 withdrawals in the control group, so 129 cases in the treatment group and 132 cases in the control group completed the trial. After treatment, LVEF increased and NT-pro BNP level decreased in both groups (
P
<0.05); compared with those in the control group, LVEF increased and NT-pro BNP level decreased in the treatment group (
P
<0.05). The total rate of graded improvement of cardiac function in the treatment group (97.67%, 126/129 cases) was higher than that in the control group (84.09%, 111/132 cases) (
P
<0.05). After treatment, the Minnesota heart failure quality of life score, anxiety score, and depression score were lower in both groups (
P
<0.05), and the above scores in the treatment group were lower than those in the control group (
P
<0.05). After 6-month treatment, there was no death event in both groups, and there was no significant difference in the major incidence of cardiovascular adverse events between the treatment group (25.58%, 33/129 cases) and the control group (33.33%, 44/132 cases) (
P
>0.05). The rate of re-hospitalization in treatment group (14.73%, 19/129 cases) was lower than that in control group (30.30%, 40/132 cases) (
P
<0.05).
Conclusion
2
Bushen Huoxue Formula
can increase LVEF, reduce NT-pro BNP, improve quality of life, improve anxiety and depression, and reduce the rate of re-hospitalization in patients of heart failure with mid-range ejection fraction with syndrome of
qi
deficiency and blood stasis.
李莹莹 , 王华 . 目前对射血分数中间值的心力衰竭的认识 [J]. 中国循环杂志 , 2022 , 37 ( 7 ): 748 - 752 .
LUSCHER TF . Heart failure and left ventricular remodeling in HFrEF and HFpEF [J]. Eur Heart J , 2016 , 37 ( 5 ): 423 - 424 .
DUNLAY SM , ROGER VL , REDFIELD MM . Epidemiology of heart failure with preserved ejection fraction [J]. Nat Rev Cardiol , 2017 , 14 ( 10 ): 591 - 602 .
朱明军 . 中医药治疗慢性心力衰竭临床疗效评价与思考 [J]. 北京中医药大学学报 , 2023 , 46 ( 7 ): 902 - 907 .
孔繁达 , 张艳 , 朱爱松 , 等 . 补肾活血方对慢性心力衰竭大鼠心功能及肾组织水通道蛋白2的影响 [J]. 中医杂志 , 2019 , 60 ( 6 ): 522 - 526 .
何佳 , 付博 , 张艳 , 等 . 补肾活血复方调控Wnt通路抑制心力衰竭心肌损伤及细胞凋亡的机制研究 [J]. 中华中医药学刊 , 2023 , 41 ( 7 ): 65 - 69,261 .
中华医学会心血管病学分会心力衰竭学组 , 中国医师协会心力衰竭专业委员会 , 中华心血管病杂志编辑委员会 . 中国心力衰竭诊断和治疗指南2018 [J]. 中华心力衰竭和心肌病杂志 , 2018 , 2 ( 4 ): 196 - 225 .
冠心病中医临床研究联盟 , 中国中西医结合学会心血管疾病专业委员会 , 中华中医药学会心病分会 , 等 . 慢性心力衰竭中医诊疗专家共识 [J]. 中医杂志 , 2014 , 55 ( 14 ): 1258 - 1260 .
葛均波 , 徐永健 , 王辰 . 内科学 [M]. 9版 . 北京 : 人民卫生出版社 , 2018 : 168 .
迟楠 . 基于“心-脑-肾轴”理论观察补肾活血复方治疗慢性心衰的临床疗效 [D]. 沈阳 : 辽宁中医药大学 , 2020 .
郑筱萸 . 中药新药临床研究指导原则(试行) [M]. 北京 : 中国医药科技出版社 , 2002 : 83 - 84 .
张明园 , 何燕玲 . 精神科评定量表手册 [M]. 长沙 : 湖南科学技术出版社 , 2015 : 143 - 147 .
汤毓华 , 张明园 . 汉密顿焦虑量表(HAMA) [J]. 上海精神医学 , 1984 , 2 ( 2 ): 61 - 64 .
RECTOR TS , KUBO S , COHN JN . Patients' self assessment of their congestion heart failure [J]. Heart Fail , 1987 , 3 ( 2 ): 198 - 209 .
刘诗瑶 . 基于“心肾理论”探究补肾活血中药治疗慢性心衰的临床疗效观察 [D]. 沈阳 : 辽宁中医药大学 , 2021 .
TSUTSUI H . Recent advances in the pharmacological therapy of chronic heart failure: evidence and guidelines [J]. Pharmacol Ther , 2022 , 238 : 108185 . doi: 10. 1016/j.pharmthera.2022.10818 http://dx.doi.org/10.1016/j.pharmthera.2022.10818 .
REIMER AM , ZIERATH R , CLAGGETT B , et al . Association of left ventricular systolic function with incident heart failure in late life [J]. JAMA Cardiol , 2021 , 6 ( 5 ): 509 - 520 .
HENDRICKS S , DYKUN I , BALCER B , et al . Higher BNP/NT-pro BNP levels stratify prognosis equally well in patients with and without heart failure:a meta analysis [J]. ESC Heart Fail , 2022 , 9 ( 5 ): 3198 - 3209 .
陈存芳 , 贾博 , 江珊 , 等 . 沙库巴曲缬沙坦治疗射血分数中间值心力衰竭患者的疗效及预后 [J]. 中国新药与临床杂志 , 2020 , 39 ( 2 ): 88 - 92 .
王雅琴 , 张艳 , 张伟 . 冠心舒通胶囊治疗心血瘀阻型冠心病心力衰竭的临床疗效 [J]. 中国实验方剂学杂志 , 2023 , 29 ( 7 ): 153 - 159 .
PIEPENBURG SM , FALLER H , STORK S , et al . Symptom patterns and clinical outcomes in women versus men with systolic heart failure and depression [J]. Clin Res Cardiol , 2019 , 108 ( 3 ): 244 - 253 .
JHA MK , OAMAR A , VADUGANATHAN M , et al . Screening and management of depression in patients with cardiovascular disease: JACC state-of-the-art review [J]. J Am Coll Cardiol , 2019 , 73 ( 14 ): 1827 - 1845 .
林祉均 , 陈梓欣 , 董鑫 , 等 . 慢性心力衰竭伴焦虑抑郁机理及中医药诊治特色与思考 [J]. 北京中医药大学学报 , 2021 , 44 ( 12 ): 1133 - 1140 .
CAPUTO I , BERTOLDI G , DRIUSSI G , et al . The RAAS goodfellas in cardiovascular system [J]. J Clin Med , 2023 , 12 ( 21 ): 6873 .
VESKOVIC J , CVETKOVIC M , TAHIROVIC E , et al . Depression, anxiety, and quality of life as predictors of rehospitalization in patients with chronic heart failure [J]. BMC Cardiovasc Disord , 2023 , 23 ( 1 ): 525 .
0
浏览量
5
下载量
1
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号